ES2172417B1 - Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden. - Google Patents

Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.

Info

Publication number
ES2172417B1
ES2172417B1 ES200001934A ES200001934A ES2172417B1 ES 2172417 B1 ES2172417 B1 ES 2172417B1 ES 200001934 A ES200001934 A ES 200001934A ES 200001934 A ES200001934 A ES 200001934A ES 2172417 B1 ES2172417 B1 ES 2172417B1
Authority
ES
Spain
Prior art keywords
improved form
pharmaceutical compositions
azithromycin monohydrate
monohidrate
azitromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200001934A
Other languages
English (en)
Other versions
ES2172417A1 (es
Inventor
Pardo Gabriel Banon
De Casa-Juana Munoz Miquel Fau
Vintro Jose Maria Gelpi
Hernandez Pedro Gonzalez
Garcia Julia Lopez
Ribota Ana Maria Riano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quimica Sintetica SA
Original Assignee
Quimica Sintetica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimica Sintetica SA filed Critical Quimica Sintetica SA
Priority to ES200001934A priority Critical patent/ES2172417B1/es
Priority to AU2001272695A priority patent/AU2001272695A1/en
Priority to PCT/IB2001/001327 priority patent/WO2002010181A1/en
Publication of ES2172417A1 publication Critical patent/ES2172417A1/es
Application granted granted Critical
Publication of ES2172417B1 publication Critical patent/ES2172417B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparación y composiciones farmacéuticas que la comprenden. La forma mejorada de azitromicina monohidrato de menor higroscopicidad se caracteriza por ser más densa y fuerte y por poseer unos valores de: densidad aparente de llenado no inferior a 0,35 g/ml; y densidad aparente golpeada no inferior a 0,50 g/ml. El procedimiento de preparación de una forma mejorada de azitromicina monohidrato, se caracteriza por someter la azitromicina monohidrato higroscópica a un proceso de compactación mediante presión. La invención también se refiere a una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de la forma mejorada de azitromicina monohidrato en asociación con al menos un diluyente inerte adecuado farmacéuticamente aceptable.
ES200001934A 2000-07-31 2000-07-31 Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden. Expired - Fee Related ES2172417B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200001934A ES2172417B1 (es) 2000-07-31 2000-07-31 Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
AU2001272695A AU2001272695A1 (en) 2000-07-31 2001-07-25 Azithromocin monohydrate with lower hygroscopicity, preparation method and pharmaceutical compositions which include it
PCT/IB2001/001327 WO2002010181A1 (en) 2000-07-31 2001-07-25 Azithromocin monohydrate with lower hygroscopicity, preparation method and pharmaceutical compositions which include it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001934A ES2172417B1 (es) 2000-07-31 2000-07-31 Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.

Publications (2)

Publication Number Publication Date
ES2172417A1 ES2172417A1 (es) 2002-09-16
ES2172417B1 true ES2172417B1 (es) 2003-09-16

Family

ID=8494518

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001934A Expired - Fee Related ES2172417B1 (es) 2000-07-31 2000-07-31 Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.

Country Status (3)

Country Link
AU (1) AU2001272695A1 (es)
ES (1) ES2172417B1 (es)
WO (1) WO2002010181A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
AP2003002906A0 (en) 2001-05-22 2003-12-31 Pfizer Prod Inc Crystal forms of azithromycin
GB0214277D0 (en) * 2002-06-20 2002-07-31 Biochemie Gmbh Organic compounds
GB0224197D0 (en) * 2002-10-17 2002-11-27 Biochemie Gmbh Organic compounds
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
MX2011009548A (es) 2009-03-13 2011-12-14 Da Volterra Composiciones y metodos para la eliminacion de bacterias gram-negativas.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
ATE469910T1 (de) * 1999-06-29 2010-06-15 Sandoz Ag Azithromycinmonohydrat

Also Published As

Publication number Publication date
ES2172417A1 (es) 2002-09-16
WO2002010181A1 (en) 2002-02-07
AU2001272695A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
MXPA04005105A (es) Formulaciones de acitromicina directamente compresibles.
WO2002013793A3 (en) Method of making tablets and tablet compositions produced therefrom
MA26880A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation.
ES2172417B1 (es) Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
MY116915A (en) Substituted indazole analogs
JP2002541233A5 (es)
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
WO1997038679A3 (en) Fast disintegrating oral dosage form
CA2171448A1 (en) 3-(3,4-dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
CA2159450A1 (en) 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
CO5390076A1 (es) Composiciones farmaceuticas
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
JO2239B1 (en) Method for preparing benzothophen derivatives
MXPA04005755A (es) Combinacion de inhibidores de proteasa dependientes del citocromo p450.
PE20000066A1 (es) Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion
ECSP024389A (es) Composiciones farmaceuticas solidas de valsartan
CA2397828A1 (en) Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
JP2005531593A5 (es)
IL110830A0 (en) 9-chlor-prostaglandin derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
AU2001225432A1 (en) Novel podophyllotoxin compositions
CA2253080A1 (en) 5-substituted picolinic acid compounds and their production process
NO880586L (no) Polypropylen-formmasse.
UA92134C2 (ru) Соединение, обладающее анти-вгс действием, и фармацевтическая композиция, содержащая его

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020916

Kind code of ref document: A1

Effective date: 20020916

FG2A Definitive protection

Ref document number: 2172417B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20110819